Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1981 1
1982 1
1984 1
1985 2
1987 2
1988 2
1990 5
1991 6
1992 2
1993 7
1994 5
1995 10
1996 7
1997 14
1998 16
1999 17
2000 36
2001 20
2002 30
2003 30
2004 35
2005 42
2006 57
2007 72
2008 65
2009 60
2010 82
2011 93
2012 115
2013 129
2014 95
2015 74
2016 77
2017 92
2018 89
2019 92
2020 86
2021 70
2022 72
2023 62
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

1,597 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Antiplatelet Use in Ischemic Stroke.
Kamarova M, Baig S, Patel H, Monks K, Wasay M, Ali A, Redgrave J, Majid A, Bell SM. Kamarova M, et al. Ann Pharmacother. 2022 Oct;56(10):1159-1173. doi: 10.1177/10600280211073009. Epub 2022 Jan 29. Ann Pharmacother. 2022. PMID: 35094598 Free PMC article. Review.
In the acute phase (first 21 days postinitial stroke), these medications have higher efficacy for preventing further stroke when combined, but long-term combination therapy is associated with higher hemorrhage rates. Antiplatelet treatment failure is influenced by poor adh …
In the acute phase (first 21 days postinitial stroke), these medications have higher efficacy for preventing further stroke when combined, b …
The genetics of antiplatelet drug resistance.
Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. Feher G, et al. Clin Genet. 2009 Jan;75(1):1-18. doi: 10.1111/j.1399-0004.2008.01105.x. Epub 2008 Nov 29. Clin Genet. 2009. PMID: 19067731 Review.
However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome o …
However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individ …
Clopidogrel Pharmacogenetics.
Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Pereira NL, et al. Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811. Circ Cardiovasc Interv. 2019. PMID: 30998396 Free PMC article. Review.
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active …
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of fun …
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Tantry US, Gurbel PA. Tantry US, et al. Curr Pharm Des. 2013;19(21):3795-815. doi: 10.2174/1381612811319210006. Curr Pharm Des. 2013. PMID: 23286432 Review.
However, pharmacodynamic studies revealed various limitations of clopidogrel metabolism and numerous factors such as genetic and, drug-drug interactions influence the antiplatelet response to clopidogrel therapy. ...The introduction of generic clopidog …
However, pharmacodynamic studies revealed various limitations of clopidogrel metabolism and numerous factors such as genetic and, …
The pharmacogenetics of antiplatelet agents: towards personalized therapy?
Ahmad T, Voora D, Becker RC. Ahmad T, et al. Nat Rev Cardiol. 2011 Aug 9;8(10):560-71. doi: 10.1038/nrcardio.2011.111. Nat Rev Cardiol. 2011. PMID: 21826075 Review.
Considerable variability exists in how individual patients respond to oral antiplatelet therapy, specifically to aspirin and to P2Y(12)-receptor inhibitors such as clopidogrel. ...However, several fundamental questions surrounding the information gained from genotyp …
Considerable variability exists in how individual patients respond to oral antiplatelet therapy, specifically to aspirin and to P2Y(1 …
The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.
Li J, Yang J, Yu Q, Chen L, Shi X, Su J, Zhu K. Li J, et al. J Clin Lab Anal. 2022 Oct;36(10):e24690. doi: 10.1002/jcla.24690. Epub 2022 Sep 10. J Clin Lab Anal. 2022. PMID: 36087301 Free PMC article.
PURPOSE: Clopidogrel resistance (CR) is mostly caused by interindividual variability of the platelet inhibition of clopidogrel, which may induce cardiovascular events. ...CONCLUSIONS: Our findings were likely to provide fresh understanding for the new mechanism of …
PURPOSE: Clopidogrel resistance (CR) is mostly caused by interindividual variability of the platelet inhibition of clopidogrel …
Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.
Marcone S, Dervin F, Fitzgerald DJ. Marcone S, et al. J Thromb Haemost. 2015 Jun;13 Suppl 1:S323-31. doi: 10.1111/jth.12943. J Thromb Haemost. 2015. PMID: 26149042 Free article. Review.
Antiplatelet agents represent the mainstay of acute coronary syndrome (ACS) therapy to prevent ischemic events and to improve safety in patients undergoing percutaneous coronary intervention. However, despite the availability of several drugs and the use of dual antipla …
Antiplatelet agents represent the mainstay of acute coronary syndrome (ACS) therapy to prevent ischemic events and to improve safety …
The state of periprocedural antiplatelet therapy after recent trials.
Desai NR, Bhatt DL. Desai NR, et al. JACC Cardiovasc Interv. 2010 Jun;3(6):571-83. doi: 10.1016/j.jcin.2010.04.008. JACC Cardiovasc Interv. 2010. PMID: 20630450 Free article. Review.
The third-generation thienopyridine, prasugrel, as well as nonthienopyridine inhibitors of the P2Y(12) receptor such as ticagrelor and cangrelor address these shortcomings, offering more potent, consistent, and rapid platelet inhibition. ...There are myriad novel co …
The third-generation thienopyridine, prasugrel, as well as nonthienopyridine inhibitors of the P2Y(12) receptor such as ticagrelor an …
Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.
Lau WC, Gurbel PA. Lau WC, et al. Pharm Res. 2006 Dec;23(12):2691-708. doi: 10.1007/s11095-006-9084-4. Epub 2006 Oct 24. Pharm Res. 2006. PMID: 17061171 Review.
However, the mechanism of antiplatelet drug resistance remains incompletely characterized, and a sensitive and specific assay of aspirin and clopidogrel effect that reliably predicts treatment failure has not emerged. To date, evidence supporting antiplate …
However, the mechanism of antiplatelet drug resistance remains incompletely characterized, and a sensitive and specific …
A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.
Fayaz SM, Rajanikant GK. Fayaz SM, et al. Curr Pharm Des. 2012;18(12):1625-34. doi: 10.2174/138161212799958558. Curr Pharm Des. 2012. PMID: 22360514 Review.
P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of t …
P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatel …
1,597 results